Your browser doesn't support javascript.
loading
C-reactive protein to lymphocyte count ratio is a promising novel marker in hepatitis C infection: the clear hep-c study.
Demirkol, Muhammed Emin; Aktas, Gulali; Bilgin, Satilmis; Kahveci, Gizem; Kurtkulagi, Ozge; Atak, Burcin Meryem; Duman, Tuba Taslamacioglu.
Afiliação
  • Demirkol ME; Abant Izzet Baysal University Hospital, Department of Internal Medicine - Bolu, Turkey.
  • Aktas G; Abant Izzet Baysal University Hospital, Department of Internal Medicine - Bolu, Turkey.
  • Bilgin S; Abant Izzet Baysal University Hospital, Department of Internal Medicine - Bolu, Turkey.
  • Kahveci G; Abant Izzet Baysal University Hospital, Department of Internal Medicine - Bolu, Turkey.
  • Kurtkulagi O; Abant Izzet Baysal University Hospital, Department of Internal Medicine - Bolu, Turkey.
  • Atak BM; Abant Izzet Baysal University Hospital, Department of Internal Medicine - Bolu, Turkey.
  • Duman TT; Abant Izzet Baysal University Hospital, Department of Internal Medicine - Bolu, Turkey.
Rev Assoc Med Bras (1992) ; 68(6): 838-841, 2022.
Article em En | MEDLINE | ID: mdl-35766701
OBJECTIVE: Chronic hepatitis C (CHC) is one of the most important health problems affecting the significant rate of world population and it may lead to cirrhosis and hepatocellular carcinoma. C-reactive protein to lymphocyte count ratio (CLR) is used in estimating inflammatory burden. Therefore, this study aimed to compare CLR values between CHC patients and healthy controls and between CHC patients with and without fibrosis. METHODS: Patients with CHC infection who visited outpatient and inpatient internal medicine clinics of our institution between January 2021 and December 2021 were enrolled to this retrospective study. CLR of the patients with CHC and healthy controls were compared. We further compared CLR of CHC patients with and without fibrosis. RESULTS: Median CLR of CHC and control subjects was 2.61 (5.13%) and 0.31 (0.37%), respectively. CLR of the CHC group was significantly increased compared to the CLR of the controls (p<0.001). There was a significant positive correlation between CLR and APRI score (r=0.15, p=0.04). The sensitivity and specificity of CLR in determining CHC above 0.58% level were 84% and 82%, respectively (AUC: 0.884, p<0.001, 95%CI 0.84-0.93). In subgroup analysis, CLR was 3.97 (6.6%) for CHC patients with fibrosis and 1.7 (4.4%) for CHC subjects without fibrosis (p=0.001). CONCLUSION: Increased CLR in patients with CHC may be an alarming finding of liver fibrosis, as CLR is associated with both CHC and hepatic fibrosis.
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hepatite C Crônica / Neoplasias Hepáticas Tipo de estudo: Diagnostic_studies / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Rev Assoc Med Bras (1992) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Turquia País de publicação: Brasil
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hepatite C Crônica / Neoplasias Hepáticas Tipo de estudo: Diagnostic_studies / Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Rev Assoc Med Bras (1992) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Turquia País de publicação: Brasil